From the Department of Clinical Research, Sheppard Pratt Health System, Baltimore, MD.
J ECT. 2021 Jun 1;37(2):84-87. doi: 10.1097/YCT.0000000000000724.
Electroconvulsive therapy (ECT) is a mainstay in both acute and long-term management of difficult-to-treat depression. However, frequent acute courses of ECT or prolonged maintenance ECT treatment may increase adverse-effect burden and/or reduce patient acceptability. Therefore, we investigated the effectiveness of adjunctive vagus nerve stimulation (VNS) therapy as an alternative strategy for long-term maintenance treatment in ECT-responsive patients.
This retrospective chart review identified maintenance ECT patients with unipolar (n = 5) and bipolar depression (n = 5) from 2 large hospital systems who had a history of ECT response, but the patients had significant residual incapacitating symptoms or increasing concerns regarding the burden associated with ECT and opted to receive adjunctive VNS therapy. The patients were followed for 2 years after VNS implantation. Response and remission were defined as Clinical Global Impression-Severity scale scores of ≤2 and 1, respectively, obtained at 1- and 2-year postimplantation compared with just before VNS implantation.
One-year postimplantation, 6 of 10 had responded of which 5 met remission criteria. All 10 patients benefited from adjunctive VNS therapy with either fewer hospitalizations and/or ECT sessions. Seven of 10 stopped maintenance ECT by the end of year 1; an additional patient stopped maintenance ECT by year 2. No patients required an acute course of ECT during the 2-year follow-up. There was a statistically significant reduction (P < 0.0001) in mean (SD) Clinical Global Impression-Severity scale scores between baseline (5.4 [0.51]) and the 1-year postimplantation (2.1 [1.37]) time points, and between baseline and the 2-year postimplantation (2.3 [1.16]) time points, whereas no difference existed between the 1- and 2-year postimplantation time points.
Vagus nerve stimulation therapy may be a useful maintenance strategy in patients with difficult-to-treat depression receiving maintenance ECT.
电抽搐治疗(ECT)是治疗难治性抑郁症的急性期和长期管理的主要手段。然而,频繁的急性 ECT 疗程或延长的维持 ECT 治疗可能会增加不良反应负担和/或降低患者的接受度。因此,我们研究了迷走神经刺激(VNS)治疗作为 ECT 反应患者的长期维持治疗的替代策略的有效性。
这项回顾性图表回顾从 2 家大型医院系统中确定了单相(n=5)和双相抑郁(n=5)的维持 ECT 患者,他们有 ECT 反应的病史,但患者有明显的残留致残症状或对 ECT 相关负担的担忧增加,并选择接受辅助 VNS 治疗。患者在 VNS 植入后随访 2 年。反应和缓解定义为临床总体印象严重程度量表评分分别在植入后 1 年和 2 年时≤2 和 1,与植入前 VNS 相比。
植入后 1 年,10 例中有 6 例有反应,其中 5 例符合缓解标准。所有 10 例患者均受益于辅助 VNS 治疗,要么减少住院和/或 ECT 次数。10 例中有 7 例在第 1 年末停止维持 ECT;第 2 年末又有 1 例患者停止维持 ECT。在 2 年的随访期间,没有患者需要进行急性 ECT 疗程。基线时(5.4 [0.51])和植入后 1 年(2.1 [1.37])之间,以及基线和植入后 2 年(2.3 [1.16])之间,平均(SD)临床总体印象严重程度量表评分存在统计学显著降低(P < 0.0001),而 1 年和植入后 2 年之间没有差异。
迷走神经刺激治疗可能是接受维持 ECT 的难治性抑郁症患者的一种有用的维持策略。